Galderma articles

Galderma is certainly the heavyweight for rosacea treatments and skincare. Rosacea sufferers will be familiar with Metrogel 1% and Oracea as well as their Cetaphil skincare range. More recently Galderma has gained approval for Mirvaso and also has CD5024/Ivermectin in development.

 

Recent Posts

Cetaphil Gentle Skin Cleansing Cloths, no rinsing needed

I feel like a bit of a Galderma PR machine at the moment, but Galderma do seem to be doing a lot. Maybe this product is yet another step in Galderma’s quest  to own the Rosacea Market. So coming soon is a moist cloth version of Cetaphil Gentle Skin Cleanser. Have you ever wished that […]

Continue Reading

Mirvaso launches promotional rediswrong.com web site

Galderma is ramping up its promotion of Mirvaso with the launch of a web site to promote the idea that a red face is just wrong. The site is a funnel page, attempting to direct you over to mirvaso.com. This type of web site is known as a `direct to consumer symptom awareness campaign’ – […]

Continue Reading

Mirvaso has been approved across Europe

News today that Mirvaso has gained approval  or Marketing Authorisation as they call it, by the European Commission. This means that Mirvaso is approved for sale and will soon be available across the European Community, at the will and availability of Galderma. So Mirvaso is now approved for sale in Austria, Belgium, Bulgaria, Croatia, Cyprus, […]

Continue Reading

Nestle now calling the shots at Galderma

Galderma, the biggest pharmaceutical company of interest to rosacea sufferers has had a subtle, but potentially important change in ownership. Galderma was created in 1981 as a joint venture between L’Oréal and Nestlé and is of course known for their prescription products like Metrogel, Oracea and Mirvaso as well as skincare products like Cetaphil. So […]

Continue Reading

Mirvaso Gel Judged Safe and Efficacious Long Term

This just published paper, in the peer-reviewed Journal of Drugs in Dermatology, again asserts that Mirvaso is “efficacious and safe“ for daily use over 1 year. This study details a trial of 345 users over a year, whilst the Mirvaso Prescribing Information quotes results from 276 users over 1 year. The previously published long term […]

Continue Reading

Top